Cargando…

Ocular Itch Relief with Alcaftadine 0.25% Versus Olopatadine 0.2% in Allergic Conjunctivitis: Pooled Analysis of Two Multicenter Randomized Clinical Trials

INTRODUCTION: The efficacy and safety of the once-daily topical ophthalmic solutions, alcaftadine 0.25% and olopatadine 0.2%, in preventing ocular itching associated with allergic conjunctivitis were evaluated. METHODS: Pooled analysis was conducted of two double-masked, multicenter, active- and pla...

Descripción completa

Detalles Bibliográficos
Autores principales:	McLaurin, Eugene B., Marsico, Nicholas P., Ackerman, Stacey L., Ciolino, Joseph B., Williams, Julia M., Villanueva, Linda, Hollander, David A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4209090/ https://www.ncbi.nlm.nih.gov/pubmed/25260889 http://dx.doi.org/10.1007/s12325-014-0155-3

Ejemplares similares

Effect of alcaftadine 0.25% on ocular itch associated with seasonal or perennial allergic conjunctivitis: a pooled analysis of two multicenter randomized clinical trials
por: Ciolino, Joseph B, et al.
Publicado: (2015)

A multicenter evaluation of the efficacy and duration of action of alcaftadine 0.25% and olopatadine 0.2% in the conjunctival allergen challenge model
por: Ackerman, Stacey, et al.
Publicado: (2013)

Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis
por: Ayyappanavar, Shruti, et al.
Publicado: (2021)

Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis
por: Dudeja, Lakshey, et al.
Publicado: (2019)

Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%
por: Greiner, Jack V, et al.
Publicado: (2011)

Update and clinical utility of alcaftadine ophthalmic solution 0.25% in the treatment of allergic conjunctivitis
por: Chigbu, DeGaulle I, et al.
Publicado: (2015)

Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis
por: Ono, Santa J, et al.
Publicado: (2011)

Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis
por: McLaurin, Eugene, et al.
Publicado: (2017)

Brimonidine Ophthalmic Solution 0.025% for Reduction of Ocular Redness: A Randomized Clinical Trial
por: McLaurin, Eugene, et al.
Publicado: (2018)

Projected 24-hour post-dose ocular itching scores post-treatment with olopatadine 0.7% versus 0.2%
por: Fidler, Matthew L., et al.
Publicado: (2018)

Allergic contact dermatitis of both eyes caused by alcaftadine 0.25%: a case report
por: Kim, Jae Hyuk, et al.
Publicado: (2019)

Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies
por: Epstein, Arthur B, et al.
Publicado: (2009)

Efficacy of 0.05% epinastine and 0.1% olopatadine for allergic conjunctivitis as seasonal and preseasonal treatment
por: Mizoguchi, Takanori, et al.
Publicado: (2017)

364 Zero Itch in Eyes Treated With Olopatadine Hydrochloride Ophthalmic Solution, 0.2% in Bilateral Conjunctival Allergen Challenge Studies
por: Blaiss, Michael S., et al.
Publicado: (2012)

Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops
por: Uchio, Eiichi
Publicado: (2008)

Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model
por: Torkildsen, Gail, et al.
Publicado: (2015)

Peculiar Properties of the La(0.25)Ba(0.25)Sr(0.5)Co(0.8)Fe(0.2)O(3−δ) Perovskite as Oxygen Reduction Electrocatalyst
por: Aliotta, Chiara, et al.
Publicado: (2023)

Topical Olopatadine Hydrochloride versus Ketotifen Fumarate for Allergic Conjunctivitis
por: Patel, Dharmistha, et al.
Publicado: (2018)

Efficacy of olopatadine hydrochloride 0.1%, emedastine difumarate 0.05%, and loteprednol etabonate 0.5% for Chinese children with seasonal allergic conjunctivitis: a randomized vehicle‐controlled study
por: Liu, Rui‐fen, et al.
Publicado: (2016)

Efficacy and Toxicity Evaluation of Bepotastine Besilate 1.5% Preservative-Free Eye Drops Vs Olopatadine Hydrochloride 0.2% Bak-Preserved Eye Drops in Patients with Allergic Conjunctivitis
por: Marini, María Cecilia, et al.
Publicado: (2023)

Low‐dose brimonidine for relief of ocular redness: integrated analysis of four clinical trials
por: Ackerman, Stacey L, et al.
Publicado: (2018)

Olopatadine ophthalmic solution suppresses substance P release in the conjunctivitis models
por: Tamura, Tadafumi
Publicado: (2012)

Comparison of olopatadine with ketotifen for allergic conjunctivitis: a meta-analysis study
por: Li, Shiyu, et al.
Publicado: (2023)

A Comparative Study of 0.25% Levobupivacaine, 0.25% Ropivacaine, and 0.25% Bupivacaine in Paediatric Single Shot Caudal Block
por: Sharma, Jagdeep, et al.
Publicado: (2018)

Anti-Plaque and Anti-Gingivitis Efficacy of 0.25% Lemongrass Oil and 0.2% Chlorhexidine Mouthwash in Children
por: Akula, Sreekumar, et al.
Publicado: (2021)

A comparison of epidural infusion of 0.2, 0.25, and 0.3% ropivacaine with fentanyl after unilateral total knee arthroplasty
por: Lee, Jae Ho, et al.
Publicado: (2013)

Maintenance of remission with low-dose olopatadine hydrochloride for itch in well-controlled chronic urticaria
por: Makino, Teruhiko, et al.
Publicado: (2012)

Evaluation of Photocatalytic Performance of Nano-Sized Sr(0.9)La(0.1)TiO(3) and Sr(0.25)Ca(0.25)Na(0.25)Pr(0.25)TiO(3) Ceramic Powders for Water Purification
por: Jovanoski Kostić, Aleksandra, et al.
Publicado: (2022)

Critical phenomena and estimation of the spontaneous magnetization from a mean field analysis of the magnetic entropy change in La(0.7)Ca(0.1)Pb(0.2)Mn(0.95)Al(0.025)Sn(0.025)O(3)
por: Dhahri, Khadija, et al.
Publicado: (2018)

Ultrasound guided peritubal infiltration of 0.25% Bupivacaine versus 0.25% Ropivacaine for postoperative pain relief after percutaneous nephrolithotomy: A prospective double blind randomized study
por: Parikh, Geeta P, et al.
Publicado: (2014)

Comparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference
por: McCabe, Craig F, et al.
Publicado: (2012)

The effectiveness of olopatadine hydrochloride eye drops for allergic conjunctivitis: Protocol for a systematic review
por: Zi, Yingxin, et al.
Publicado: (2020)

Exchange-bias via nanosegregation in novel Fe(2−x)Mn(1+x)Al (x = −0.25, 0, 0.25) Heusler films
por: Kurdi, S., et al.
Publicado: (2020)

Hydrothermal Synthesis and Crystal Structure of a Novel Bismuth Oxide: (K(0.2)Sr(0.8))(Na(0.01)Ca(0.25)Bi(0.74))O(3)
por: Hossain, Khandaker Monower, et al.
Publicado: (2021)

A case report of allergic blepharoconjunctivis to alcaftadine
por: Sandrin, Leda Das Neves Almeida
Publicado: (2015)

Dynamic Mechanical Properties and Microstructure of an (Al(0.5)CoCrFeNi)(0.95)Mo(0.025)C(0.025) High Entropy Alloy
por: Wang, Bingfeng, et al.
Publicado: (2019)

Tin-Decorated Reduced Graphene Oxide and NaLi(0.2)Ni(0.25)Mn(0.75)O(δ) as Electrode Materials for Sodium-Ion Batteries
por: Prosini, Pier Paolo, et al.
Publicado: (2019)

Potential outstanding physical properties of novel black arsenic phosphorus As(0.25)P(0.75)/As(0.75)P(0.25) phases: a first-principles investigation
por: Liu, Fangqi, et al.
Publicado: (2022)

Caudal Epidural Analgesia in Pediatric Patients: Comparison of 0.25% Levobupivacaine and 0.25% Ropivacaine in Terms of Motor Blockade and Postoperative Analgesia
por: Praveen, P., et al.
Publicado: (2017)

The Safety of Besifloxacin Ophthalmic Suspension 0.6 % Used Three Times Daily for 7 Days in the Treatment of Bacterial Conjunctivitis
por: Malhotra, Ranjan, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_062p9avoo86flbc6t6863bu3bv